Cleveland Clinic is collaborating with industry biomarker developers to improve lung cancer biomarkers on the market, as well as developing volatile organic compound biomarkers of the breath, urine and blood.
A new combination epigenetic therapy could enhance activity of immune checkpoint inhibitors in lung cancer. A proof-of-concept trial of oral tetrahydrouridine (THU)-decitabine, along with nivolumab, will begin soon at Cleveland Clinic.
In his most recent ASCO Connection blog post, Cleveland Clinic oncologist Nathan Pennell, MD, PhD, discusses the complexities of moving new drugs into practice and encourages colleagues from all sides to continue the conversation.
Several trials are seeking to demonstrate that genetic alterations in cancer are more important than the site of origin. In one study, lung cancer patients are entered into one of four arms based on tumor genomic analysis.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Medicare now covers annual low-dose CT screenings for patients at greatest risk of developing lung cancer. This test can reduce lung cancer deaths in high-risk patients by 20 percent.
Practice variations in cancer treatment are inefficient and costly, but research shows that an evidence-based care path for NSCLC helps standardize treatment while preserving survival benefits and markedly decreasing costs.
After reviewing 10 years of patient experience, researchers at Cleveland Clinic confirm that SBRT has potential to cure lung cancer with minimal side effects in early-stage patients who are medically inoperable.
MAP-Lung and Alchemist Trials focus on improving cure rates for patients with lung cancer.
Large-scale Cleveland Clinic effort catalogues and targets genetic alterations that confer resistance.